APA (7th ed.) Citation

Manier, S., Dimopoulos, M., Leleu, X. P., Moreau, P., Cavo, M., Goldschmidt, H., . . . Facon, T. (2025). Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: A frailty subgroup analysis of the IMROZ trial. Haematologica, 110(9), . https://doi.org/10.3324/haematol.2024.287200

Chicago Style (17th ed.) Citation

Manier, Salomon, et al. "Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone for Transplant-ineligible Newly Diagnosed Multiple Myeloma Patients: A Frailty Subgroup Analysis of the IMROZ Trial." Haematologica 110, no. 9 (2025). https://doi.org/10.3324/haematol.2024.287200.

MLA (9th ed.) Citation

Manier, Salomon, et al. "Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone for Transplant-ineligible Newly Diagnosed Multiple Myeloma Patients: A Frailty Subgroup Analysis of the IMROZ Trial." Haematologica, vol. 110, no. 9, 2025, https://doi.org/10.3324/haematol.2024.287200.